A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension

Recruiting now

Conditions studied: Diabetes Mellitus, Hypertension

In brief

The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension

Key facts

Study ID

NCT05970237

Run by

Boryung Pharmaceutical Co., Ltd

People needed

9000

Starts

2023-07-26

Expected to finish

2025-10-21

Last updated by the study team

2025-09-15

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Those diagnosed with type 2 diabetes mellitus accompanied by hypertension who are scheduled to be administrated Trudapa Tab. or Trudapa M SR Tab.
• Those who voluntarily signed a written personal information agreement to participate in this clinical study.
• Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion.

You may not qualify if…

• Patients with secondary hypertension: Secondary hypertension is not limited to the following diseases; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.)
• Those who have a history of taking dapagliflozin within 4 weeks of baseline (Visit 1)
• Those who are expected to need insulin prescription during the study period
• Pregnant women, breast-feeding women

Where it is running

• Gachon University Gil Medical Center — Incheon, Namdong-gu, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.